With Esther Duflo, Abhijit Banerji, and Michael Kremer winning the 2019 Nobel Memorial Prize in Economic Sciences, there is renewed interest and discourse around randomised controlled trials (RCTs).
But RCTs are complex, and there seem to be lingering questions around the subject. From conceptual queries to the ethics of RCTs, here are some of those questions, answered.
—
Insights in this explainer have been sourced from J-PAL’s Introduction to Evaluations, in consultation with other sources.
Ayesha Marfatia contributed to this article.
